EVI1 protein interaction dynamics: targetable for therapeutic intervention?

Roberto Paredes; Nora Doleschall; Kathleen Connors; Bethany Geary; Stefan Meyer

doi:10.1016/j.exphem.2021.12.398

EVI1 protein interaction dynamics: targetable for therapeutic intervention?

Roberto Paredes, Nora Doleschall, Kathleen Connors, Bethany Geary, Stefan Meyer

Research output: Contribution to journal › Review article › peer-review

108 Downloads (Pure)

Abstract

High expression of the transcriptional regulator EVI1 encoded at the MECOM locus at 3q26 is one of the most aggressive oncogenic drivers in acute myeloid leukemia (AML) and carries a very poor prognosis. How EVI1 confers leukemic transformation and chemotherapy resistance in AML is subject to important ongoing clinical and experimental studies. Recent discoveries have revealed critical details on genetic mechanisms of the activation of EVI1 overexpression and downstream events of aberrantly high EVI1 expression. Here we review and discuss aspects concerning the protein interactions of EVI1 and the related proteins MDS-EVI1 and ΔEVI1 from the perspective of their potential for therapeutic intervention.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Experimental Hematology
Volume	107
Early online date	24 Dec 2021
DOIs	https://doi.org/10.1016/j.exphem.2021.12.398
Publication status	Published - 1 Mar 2022

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.exphem.2021.12.398

21-207_R1 (2)Accepted author manuscript, 1.2 MB

Cite this

@article{30b7c7c6203d485c9663666859fa33ea,

title = "EVI1 protein interaction dynamics: targetable for therapeutic intervention?",

abstract = "High expression of the transcriptional regulator EVI1 encoded at the MECOM locus at 3q26 is one of the most aggressive oncogenic drivers in acute myeloid leukemia (AML) and carries a very poor prognosis. How EVI1 confers leukemic transformation and chemotherapy resistance in AML is subject to important ongoing clinical and experimental studies. Recent discoveries have revealed critical details on genetic mechanisms of the activation of EVI1 overexpression and downstream events of aberrantly high EVI1 expression. Here we review and discuss aspects concerning the protein interactions of EVI1 and the related proteins MDS-EVI1 and ΔEVI1 from the perspective of their potential for therapeutic intervention.",

author = "Roberto Paredes and Nora Doleschall and Kathleen Connors and Bethany Geary and Stefan Meyer",

note = "Funding Information: S. Meyer received funding from CRUK, the Kay Kendall Leukaemia Fund, Blood Cancer UK, Children with Cancer, the Childhood Cancer and Leukaemia Group, and Fanconi Hope for work related to this article. Publisher Copyright: {\textcopyright} 2021 ISEH – Society for Hematology and Stem Cells",

year = "2022",

month = mar,

day = "1",

doi = "10.1016/j.exphem.2021.12.398",

language = "English",

volume = "107",

pages = "1--8",

journal = "Experimental Hematology",